Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma

Journal article


Research Areas

No matching items found.

Publication Details

Author list: Martin-Carbonero L, Barrios A, Saballs P, Sirera G, Santos J, Palacios R, Valencia ME, Alegre M, Podzamczer D, Gonzalez-Lahoz J
Publisher: Lippincott, Williams & Wilkins
Publication year: 2004
Volume number: 18
Issue number: 12
Start page: 1737
End page: 1740
Number of pages: 4
ISSN: 0269-9370
Languages: English-Great Britain (EN-GB)


Twenty-eight HIV patients either naive or failing highly active antiretroviral therapy (HAART) with moderate-advanced Kaposi's sarcoma (KS) were randomly chosen to initiate a new HAART regimen plus pegylated liposomal doxorubicin (PLD) or the new HAART regimen alone. After 48 weeks, better response rates were observed in the HAART plus PLD group (76% versus 20%). In HIV-infected patients with moderate-advanced KS, HAART alone may not be enough for KS response.


No matching items found.


No matching items found.

Last updated on 2019-23-08 at 11:15